-+ 0.00%
-+ 0.00%
-+ 0.00%

Newbury Pharma signs license, supply deal with existing partner to launch guanfacine in Sweden

PUBT·08/17/2026 13:16:14
Listen to the news
Newbury Pharma signs license, supply deal with existing partner to launch guanfacine in Sweden
  • Newbury signed a license and supply deal with an existing partner to register, supply, and launch guanfacine tablets in Sweden.
  • Product targets ADHD in children and adolescents; prolonged-release tablets in 1 mg to 4 mg strengths.
  • Regulatory filing expected soon; launch planned following approval.
  • Relevant Swedish market estimated at EUR 17 million annually, based on DLMI Nordic Pharma Insights.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Newbury Pharmaceuticals AB published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.